Fuente: Oncology News Central

Oncology News Central publicó una nota reciente relacionada con cáncer de la mujer. En OncoGine se incorpora en español como referencia editorial breve para seguimiento profesional. The DESTINY-Breast05 trial found that trastuzumab deruxtecan significantly improved invasive disease–free survival versus trastuzumab emtansine in HER2-positive breast cancer.

Referencia consultada: DESTINY-Breast05 Trial: Research Recap

Fuente original: https://www.oncologynewscentral.com/breast-cancer/her2-directed-adc-improves-invasive-disease-free-survival-in-high-risk-early-breast-cancer-research-recap